Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
Oncotarget|December 15, 2018
Targeting mesothelin in ovarian cancerAzam Ghafoor, Anish Thomas, Raffit Hassan
The Oncologist|January 7, 2015
Advances in anticancer immunotoxin therapyChristine Alewine, Raffit Hassan, Ira Pastan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Mesothelin: a new target for immunotherapyRaffit Hassan, Tapan Bera, Ira Pastan
Journal of Oncology Practice|March 9, 2018
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline SummaryHedy L Kindler, Nofisat Ismaila, Raffit Hassan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 7, 2025
Germline BAP1 Mutation-Associated Mesothelioma: A Biologically and Clinically Distinct EntityAzam Ghafoor, Catherine Ostos Perez, Raffit Hassan
Lung Cancer (Amsterdam, Netherlands)|May 31, 2011
Chemotherapy and targeted therapies for unresectable malignant mesotheliomaRonan Joseph Kelly, Elad Sharon, Raffit Hassan
The Lancet. Oncology|June 15, 2016
Antibody-drug conjugates for cancer therapyAnish Thomas, Beverly A Teicher, Raffit Hassan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2020
Response to Letter to the Editor by Yang et alRaffit Hassan, Manjistha Sengupta, Junko Murai, et al.
The Lancet. Oncology|February 3, 2020
Orbital metastases from malignant mesotheliomaIdrees Mian, Emerson Padiernos, Raffit Hassan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 18, 2007
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumorsYujian Zhang, Laiman Xiang, Raffit Hassan, et al.
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
Oncotarget|December 15, 2018
Targeting mesothelin in ovarian cancerAzam Ghafoor, Anish Thomas, Raffit Hassan
The Oncologist|January 7, 2015
Advances in anticancer immunotoxin therapyChristine Alewine, Raffit Hassan, Ira Pastan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Mesothelin: a new target for immunotherapyRaffit Hassan, Tapan Bera, Ira Pastan
Journal of Oncology Practice|March 9, 2018
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline SummaryHedy L Kindler, Nofisat Ismaila, Raffit Hassan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 7, 2025
Germline BAP1 Mutation-Associated Mesothelioma: A Biologically and Clinically Distinct EntityAzam Ghafoor, Catherine Ostos Perez, Raffit Hassan
Lung Cancer (Amsterdam, Netherlands)|May 31, 2011
Chemotherapy and targeted therapies for unresectable malignant mesotheliomaRonan Joseph Kelly, Elad Sharon, Raffit Hassan
The Lancet. Oncology|June 15, 2016
Antibody-drug conjugates for cancer therapyAnish Thomas, Beverly A Teicher, Raffit Hassan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2020
Response to Letter to the Editor by Yang et alRaffit Hassan, Manjistha Sengupta, Junko Murai, et al.
The Lancet. Oncology|February 3, 2020
Orbital metastases from malignant mesotheliomaIdrees Mian, Emerson Padiernos, Raffit Hassan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 18, 2007
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumorsYujian Zhang, Laiman Xiang, Raffit Hassan, et al.
Pageof 15